The U.S. Food and Drug Administration (FDA) granted a supplemental efficacy approval for Opdivo (nivolumab) on July 15, 2021. This approval indicates the FDA's review and acceptance of new data related to the drug's efficacy.
Background
Nivolumab, marketed as Opdivo, is an established therapeutic agent. Supplemental applications are a standard regulatory pathway for approved drugs to expand their utility. These applications allow manufacturers to seek approval for new indications, patient populations, dosing regimens, or other changes that impact the drug's approved use. The sponsor for this supplemental application was Bristol Myers Squibb.
What this means
A supplemental efficacy approval for an already approved drug like Opdivo (nivolumab) signifies that the FDA has evaluated new clinical data demonstrating additional or modified benefits. While the specific details of the new indication or patient population are not available in the provided data, such approvals typically lead to updates in the drug's official prescribing information, or "label." This could mean that Opdivo is now approved for a new type of cancer, a different stage of an existing cancer, or a new line of therapy. For clinicians, this means there is an expanded evidence base for using nivolumab in patient care. Researchers and patient advocates will look to the full updated label for precise details on the expanded scope of this important immunotherapy.
Source
This information was sourced from the U.S. Food and Drug Administration (FDA) through their drug approvals database. The supplemental application for Opdivo (nivolumab) (BLA 125554 S-99) was approved on July 15, 2021, and is publicly accessible on accessdata.fda.gov.